REGENERON PHARMACEUTICALS, INC. Net Income (Loss) Available to Common Stockholders, Diluted
REGENERON PHARMACEUTICALS, INC. (REGN) reported Net Income (Loss) Available to Common Stockholders, Diluted of $388.32 million for the 3-month period ending 2017-09-30, per its 10-Q filed 2017-11-08.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2017-11-08
- REGENERON PHARMACEUTICALS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2017-09-30 was $388.32M, a 46.64% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2017-06-30 was $387.74M, a 97.61% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2017-03-31 was $248.93M, a 37.20% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2016-09-30 was $264.80M, a 25.77% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. net income (loss) available to common stockholders, diluted for fiscal 2014 was $348.07M, a 17.98% decline from fiscal 2013.
- REGENERON PHARMACEUTICALS, INC. net income (loss) available to common stockholders, diluted for fiscal 2013 was $424.36M, a 45.55% decline from fiscal 2012.
- REGENERON PHARMACEUTICALS, INC. net income (loss) available to common stockholders, diluted for fiscal 2012 was $779.39M.
- REGENERON PHARMACEUTICALS, INC. net income (loss) available to common stockholders, diluted for fiscal 2011 was -$221.76M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|---|
| 2017-09-30 | $388.32M 10-Q · filed 2017-11-08 | $776.06M derived: sum of 2 quarters · filed 2017-11-08 | $1.02B 10-Q · filed 2017-11-08 | ||
| 2017-06-30 | $387.74M 10-Q · filed 2017-08-03 | $636.67M 10-Q · filed 2017-08-03 | |||
| 2017-03-31 | $248.93M 10-Q · filed 2017-05-04 | ||||
| 2016-09-30 | $264.80M 10-Q · filed 2017-11-08 | $461.02M derived: sum of 2 quarters · filed 2017-11-08 | $642.80M 10-Q · filed 2017-11-08 | ||
| 2016-06-30 | $196.22M 10-Q · filed 2017-08-03 | $186.12M 10-Q · filed 2016-08-04 | $377.98M 10-Q · filed 2017-08-03 | ||
| 2016-03-31 | $181.44M 10-Q · filed 2017-05-04 | $165.79M 10-Q · filed 2016-05-05 | |||
| 2015-09-30 | $210.54M 10-Q · filed 2016-11-04 | $405.19M derived: sum of 2 quarters · filed 2016-11-04 | $481.06M 10-Q · filed 2016-11-04 | $591.38M derived: sum of 4 quarters · filed 2016-11-04 | |
| 2015-06-30 | $194.64M 10-Q · filed 2016-08-04 | $270.66M 10-Q · filed 2016-08-04 | $380.84M derived: sum of 3 quarters · filed 2016-08-04 | $467.02M derived: sum of 4 quarters · filed 2016-08-04 | |
| 2015-03-31 | $76.02M 10-Q · filed 2016-05-05 | $186.20M derived: sum of 2 quarters · filed 2016-05-05 | $272.38M derived: sum of 3 quarters · filed 2016-05-05 | ||
| 2014-12-31 | $110.18M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-12 | $196.35M derived: sum of 2 quarters · filed 2015-11-04 | $348.07M 10-K · filed 2015-02-12 | ||
| 2014-09-30 | $86.18M 10-Q · filed 2015-11-04 | $82.52M 10-Q · filed 2014-11-04 | $237.90M 10-Q · filed 2014-11-04 | ||
| 2013-12-31 | $82.95M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-12 | $228.93M derived: sum of 2 quarters · filed 2015-02-12 | $424.36M 10-K · filed 2015-02-12 | ||
| 2013-09-30 | $145.98M 10-Q · filed 2014-11-04 | $341.41M 10-Q · filed 2014-11-04 | |||
| 2012-12-31 | $499.53M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-12 | $698.38M derived: sum of 2 quarters · filed 2015-02-12 | $779.39M 10-K · filed 2015-02-12 | ||
| 2012-09-30 | $198.84M 10-Q · filed 2013-11-05 | $279.86M 10-Q · filed 2013-11-05 | |||
| 2011-12-31 | -$221.76M 10-K · filed 2014-02-13 | ||||
| 2011-09-30 | -$62.37M 10-Q · filed 2012-10-24 | ||||
| 2010-12-31 | -$104.47M 10-K · filed 2013-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |